Vincerx Pharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 42
- Market Cap
- $23.7M
- Website
- http://vincerx.com
- Introduction
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- Conditions
- Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaHigh-risk Myelodysplastic Syndrome
- Interventions
- Drug: VIP943 (QW)Drug: VIP943 (BIW)
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Vincerx Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06034275
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
- Conditions
- Neoplasms
- Interventions
- Drug: VIP236 (Q3W)Drug: VIP236 (Q2W)
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Vincerx Pharma, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT05712889
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸NEXT Austin, Austin, Texas, United States
🇺🇸NEXT Oncology San Antonio, San Antonio, Texas, United States
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
- Conditions
- MYC OverexpressionMYC TranslocationChronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRelapsed Non Hodgkin LymphomaRichter SyndromeMYC Amplification
- Interventions
- Drug: VIP152Drug: BTKi
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Vincerx Pharma, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04978779
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
- Conditions
- Neoplasms
- Interventions
- Drug: VIP152 (BAY 1251152)Drug: VIP152 (BAY 1251152) 30 mgDrug: KeytrudaDrug: VIP152 (BAY 1251152) 15 mg
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Vincerx Pharma, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT02635672
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Avera Health, Sioux Falls, South Dakota, United States